Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $381.44 Average PT from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have earned an average rating of "Hold" from the eleven ratings firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $381.44.

Separately, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MEDP. R Squared Ltd purchased a new position in shares of Medpace during the fourth quarter worth $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace during the 4th quarter valued at about $31,000. Stone House Investment Management LLC acquired a new position in Medpace in the 3rd quarter valued at about $33,000. Ashton Thomas Securities LLC purchased a new stake in Medpace during the third quarter worth about $37,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Remove Ads

Medpace Trading Down 0.9 %

NASDAQ:MEDP traded down $2.83 during trading hours on Monday, reaching $325.73. 328,516 shares of the company were exchanged, compared to its average volume of 300,828. The stock's 50-day moving average is $341.27 and its 200-day moving average is $344.03. Medpace has a twelve month low of $302.01 and a twelve month high of $459.77. The firm has a market cap of $9.92 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.